Explore our library of publications, abstracts, and presentations.

Tippin, T, Srnka, A, Savina, P, Van Sickle, K, Naderer, O. Poster Tissue Distribution of Radioactivity after Intravenous and Oral Administration of Brincidofovir to Rats, 2016 November. AAPS.

Grimley, M, Papanicolaou, G, Prasad, V.K., Marón, G, Brundage, T, Vainorius, E, Chittick, G, Nichols, G. Poster Treatment of Adenovirus (AdV) Infection in Allogeneic Hematopoietic Cell Transplant (HCT) Patients (pts) with Brincidofovir: 24 Week Interim Results from the AdVise Trial, 2016 October. ID Week. Slide Version

Lanier, E, Foster, S, Brundage, T, Chou, S, Prichard, M, Kleiboeker, S, Wilson, C, Colville, D, Mommeja-Marin, H. Article Analysis of Mutations in the Gene Encoding Cytomegalovirus DNA Polymerase in a Phase 2 Clinical Trial of Brincidofovir Prophylaxis, 2016 July. J Infect Dis. 2016 Jul 1; 214(1): 32–35.

Grimley, M, Florescu, D, Danziger-Isakov, L, Brundage, T, Nichols G. Poster Treatment of Adenovirus Infection in Solid Organ Transplant with Brincidofovir, 2016 June. ICAAC/ASM Microbe.

Mozaffari E, Lin J, Lingohr-Smith M, Novosys Hlth. Poster Burden of Cytomegalovirus Infection Among Allogeneic Hematopoietic Cell Transplant Recipients, 2016 February. BMT Tandem Meeting.

Mozaffari E, Casciano R, Stern L, Lee Y, Patel V, LASER Analytica. Poster Clinical and Economic Consequences Associated with Cytomegalovirus Infection among Allogeneic Hematopoietic Cell Transplant Patients, 2016 February. BMT Tandem Meeting.

Mozaffari E, Lin J, Lingohr-Smith M, Novosys Hlth. Poster Double-Stranded DNA Virus Infections Among Allogeneic Hematopoietic Cell Transplant Recipients: Impact on Patient Survival and Hospital Resource Utilization, 2016 February. BMT Tandem Meeting.

Mozaffari E, Lee Y, Stern L, Patel V, Casciano R, LASER Analytica. Poster First-Year Incidence of Double-Stranded DNA Virus Infections Following Hematopoietic Cell Transplantation, 2016 February. BMT Tandem Meeting.

Mozaffari E, Stern L, Lee Y, Patel V, Casciano R, LASER Analytica. Poster First-Year Incidence of Adenovirus Infections Following Allogeneic Hematopoietic Cell Transplants in a Pediatric Population, 2016 February. BMT Tandem Meeting.

Mozaffari E, Lin J, Lingohr-Smith M, Novosys Hlth. Poster Frequency of Hospital Readmissions Post Allogeneic Hematopoietic Cell Transplantation, 2016 February. BMT Tandem Meeting.

Mozaffari E, Lin J, Lingohr-Smith M, Poster Burden of neutropenia-related hospital readmissions among hematopoietic cell transplant recipients, 2015, December. ASHP.

Lee YC, Mozaffari E, Schabert VF, Patel V, Casciano R, Poster One-year incidence of hospital readmission in hematopoietic cell transplant recipients and reasons for readmissions, 2015, December. ASHP.

Mozaffari E, Lin J, Lingohr-Smith M, Poster Healthcare resource utilization and associated costs for hematopoietic cell transplant recipients: hospital perspective, 2015, December. ASHP.

Hill J, Mayer B, Xie H, Leisenring W, Milano F, Huang M, Stevens-Ayers T, Jerome K, Nichols G, Zerr D, Schiffer J, Boeckh M, Abstract Detection of Multiple Double-Stranded DNA Viruses after Cord Blood Transplantation is Frequent and Persistent,* 2015, December. ASH. *This research was conducted by Fred Hutchison Cancer Research Center with support from Chimerix.

Lee YJ, Kim SJ, Burack D, Huang YT, Papadopoulos EB, Jakubowski A, Papanicolaou G, Poster Brincidofovir (BCV) Prophylaxis for Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV) after Hematopoietic Cell Transplantation (HCT): Clinical Experience at Memorial Sloan Kettering Cancer Center,* 2015, December. ASH. *This study was conducted by Memorial Sloan Kettering Cancer Center with support from Chimerix.

Huang YT, Kim SJ, Lee YJ, Burack D, Maloy M, Tamari R, Perales MA, Giralt S, Castro-Malaspina H, Papadopoulos EB, Jakubowski A, Papanicolaou G, Poster Infection Burden of Double Stranded DNA (dsDNA) Viruses after CD34+ Selected, T-cell Depleted (TCD) Hematopoietic Cell Transplantation (HCT) for Myeloid Malignancies at Memorial Sloan Kettering Cancer Center (MSK),* 2015, December. ASH. *This research was conducted by Memorial Sloan Kettering Cancer Center with support from Chimerix.

Florescu D, Grimley M, Bourne E, Chittick G, Brundage T, Momméja-Marin H, Marón G, Abstract Brincidofovir (BCV) for the Treatment of Adenovirus (AdV) Infection in Patients Receiving Liver Transplantation (LT), 2015, October. ID Week. Poster Brincidofovir (BCV) for the Treatment of Adenovirus (AdV) Infection in Patients Receiving Liver Transplantation (LT)

Mozaffari E, Lin J, Lingohr‐Smith M, Abstract Prevalence of Double Stranded DNA Viral Infections Among Allogeneic Hematopoietic Stem Cell Transplant (HCT) Recipients, 2015, October. ID Week.Poster Prevalence of Double Stranded DNA Viral Infections Among Allogeneic Hematopoietic Stem Cell Transplant (HCT) Recipients

Mozaffari E, Lin J, Lingohr-Smith M, Novosys Hlth. Abstract Hospital Readmissions Among Hematopoetic Stem Cell Transplantation (HCT) Recipients, 2015 September. ICAAC. Poster Hospital Readmissions Among Hematopoetic Stem Cell Transplantation (HCT) Recipients

Bae A, Sethna P, Brundage T, Mommeja-Marin H, Nichols G, Lanier R. Abstract Adenovirus (AdV) Virologic Response to Brincidofovir in Patients with Evidence of Resistance, 2015 September. ICAAC. Presentation Dedicated to Preventing and Treating Life-Threatening Viral Infections

Michael Grimley, Presentation Improved Outcomes in Allogeneic Hematopoietic Cell Transplant Patients Treated with Brincidofovir (CMX001, BCV) for Disseminated Adenovirus Disease Compared to Literature: Updated Preliminary Results from the AdVise (CMX001-304) Study 2015, March 22, EBMT Meeting.

Michael Grimley, Genovefa Papanicolaou, Gabriela Maron, Gregory Chittick, Thomas Brundage, Andrew Bae, Herve Mommeja-Marin, W. Garrett Nichols, Vonod K. Prasad, Abstract Improved Outcomes in Allogeneic Hematopoietic Cell Transplant (allo HCT) Patients Treated with Brincidofovir (CMX001, BCV) for Disseminated Adenovirus (AdV) Disease Compared to Literature: Updated Preliminary Results from AdVise (CMX001-304) Study 2015, March 22, EBMT Meeting.

Michael Grimley, Gabriela Marón, Vinod Prasad, David Jacobsohn, Jo-Anne Young, Greg Chittick, Tom Brundage, Hérve Momméja-Marin, Abstract Preliminary Results from the AdVise Study Evaluating Brincidofovir (BCV, CMX001) for the Treatment of Disseminated and High-Risk Adenovirus (AdV) Infection 2015, February 12, BMT Tandem Meeting.

Michael Grimley, MD, Presentation Preliminary Results from the AdVise Study Evaluating Brincidofovir (BCV, CMX001) for the Treatment of Disseminated and High-Risk Adenovirus (AdV) Infection 2015, February 12, BMT Tandem Meeting.

Tom Brundage, Herve Mommeja-Marin, Marion Morrison, Katherine J. Van Sickle, Abstract Brincidofovir (CMX001) Dose and Plasma Exposure Correlates with Serum Alanine Aminotransferase Elevations 2014 November, AASLD. Poster Brincidofovir (CMX001) Dose and Plasma Exposure Correlates with Serum Alanine Aminotransferase Elevations

Jo-Anne Young, Michael Grimley, David Jacobsohn, Gabriela Marón, Greg Chittick; Thomas Brundage, Hervé Momméja-Marin, Michelle Berrey, Abstract Preliminary Safety Results and Antiviral Activity from the Open-label Pilot Portion of a Phase 3 Study to Evaluate Brincidofovir (BCV) for the Treatment of Adenovirus (AdV) Infection 2014 October, ID Week, Session: 186, Presentation Preliminary Safety Results and Antiviral Activity from the Open-label Pilot Portion of a Phase 3 Study to Evaluate Brincidofovir for the Treatment of Adenovirus Infection Saturday, October 11, 2014, ID Week, Presentation No. LB-3

Foster S, Selleseth D, Prichard M, et al. Abstract Accepted for Oral Presentation. 2014 September, ICAAC. Presentation Combination Activity and Emerging Resistance Profile of Brincidofovir in CMV Prevention and Treatment.

Lanier R, et. al. Abstract Accepted for Oral Presentation. 2014 September, ICAAC. Presentation Resistance Profile of Adenovirus Exposed to Brincidofovir In Vitro and In Vivo.

Morrison M, Avery R, Kwak E, et al. Abstract Accepted for Oral Presentation. 2014 July. WTC. Presentation Switch from Existing Antivirals to Brincidofovir Leads to Improving Renal Function.

Mullane K, Florescu DF, Kwak EJ, et al. Abstract Accepted for Poster Presentation. 2014 July. WTC. Presentation Brincidofovir (CMX001) Experience in Renal Transplant Patients for Treatment of Refractory CMV Infection.

Florescu D, Mercer D, Grimley M, et al. Abstract WTC 2014 Abstract. 2014 July. WTC. Poster Brincidofovir (CMX001) for the Treatment of Serious or Life-Threatening Double-Stranded DNA Virus Infections in Patients Receiving Liver Transplant as Part of Multiorgan Transplantation.

Sethna P, Selleseth D, Bae A, et al. Abstract Brincidofovir (BCV, CMX001) Delivers High Intracellular Concentrations of Cidofovir Diphosphate. 2014 May. ICAR. Poster Brincidofovir (BCV) Delivers High Intracellular Concentrations of Cidofovir Diphosphate.

Sethna P, Bae A, Selleseth D, et al. Abstract In Vitro Selection of Brincidofovir-Resistant and Cidofovir-Resistant Human Adenovirus. 2014 May. ICAR. Poster In Vitro Selection of Brincidofovir-Resistant and Cidofovir-Resistant Human Adenovirus.

Papanicolaou G, Grimley M, Morrison M, et al. Abstract Pre-Engraftment Initiation of Brincidofovir (BCV, CMX001) in Hematopoietic Cell Transplant Recipients is Supported by Lack of Myeloid Toxicity. 2014 March. EBMT. Poster Pre-Engraftment Initiation of Brincidofovir (BCV, CMX001) in Hematopoietic Cell Transplant Recipients is Supported by Lack of Myeloid Toxicity.

Grossi IM, Foster S, Van Sickle K, et al. Abstract Efficacy and PK of Brincidofovir for Treatment of Lethal Rabbitpox (RPXV) Infection in NZW Rabbits; a Model of Human Smallpox. March 2014. SOT. Poster Efficacy and Pharmacokinetics of Brincidofovir for Treatment of Lethal Rabbitpox Virus (RPXV) Infection in NZW Rabbits: A Model of Human Smallpox.

Prasad VK, Grimley M, Papanicolaou G, et al. Oral Abstract Brincidofovir (CMX001) is Well Tolerated in Highly Immunocompromised Pediatric Patients. 2014 February. BMT.

Grimley M, Prasad V, Kurtzberg J, et al. Oral Abstract Twice—weekly Brincidofovir (BCV, CMX001) Shows Promising Antiviral Activity in Immunocompromised Transplant Patients with Asymptomatic Adenovirus Viremia. 2014 February. BMT

Papanicolaou G, Grimley M, Morrison M, et al. Abstract Pre-engraftment Initiation of Brincidofovir (CMX001) in Hematopoietic Cell Transplant Recipients is Supported by Lack of Myeloid Toxicity. 2013 December. ASH.

Tippin T, Chladek J, Keilholz L, et al. Abstract CYP42 is the Major Cytochrome P450 Involved in CMX001 Metabolism. 2013 October, September. ISSX. Poster CYP4F2 is the Major Cytochrome P450 Enzyme Involved in CMX001 Metabolism.

Trost L. Abstract Update on the Development of Brincidofovir (CMX001) for Smallpox and Other Indications. 2013 September. WHO. Presentation Update on the Development of Brincidovofir (CMX001) for Smallpox and Other Indications.

Grimley M, Chemaly R, Englund J, et al. Presentation A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation (The ADV HALT Trial). 2013 September. ICAAC. Abstract The First Interventional Trial for Adenovirus (AdV): Brincidofovir (CMX001) for AdV in HCT.

Lanier ER. Abstract Rational Design of Nucleoside Phosphonates for Intracellular Delivery Using Lipid Conjugation. 2013 August. IBT Talk. Presentation Rational Design of Nucleoside Phosphonates for Intracellular Delivery Using Lipid Conjugation.

James SH, Price NB, Hartline E, et al. Article Selection and Recombinant Phenotyping of a Novel CMX001 and Cidofovir Resistance Mutation in Human Cytomegalovirus. 2013 May. AAC. 2013, 57 (7):3321.

Lanier ER. Presentation/Slides Emerging CMV Resistance Profile for CMX001. 2013 May. ICAR. Abstract Rational Design of Nucleoside Phosphonates for Intracellular Delivery Using Lipid Conjugation.

Lanier ER. Presentation Rational Design of Nucleoside Phosphonates for Intracellular Delivery Using Lipid Conjugation.2013 May. ICAR.

Grimley M, Papanicolaou G, Prasad V, et al. Abstract CMX001 is a Potential Treatment for Adenovirus Infection: Preliminary Antiviral Efficacy Results from an Open-label, Expanded Access Study of CMX001 for the Treatment of Serious or Life-threatening Diseases Caused by Double-stranded DNA Viruses. 2013 April. EBMT. Presentation CMX001 is a Potential Treatment for Adenovirus Infection: Preliminary Antiviral Efficacy Results from an Open-label, Expanded Access Study of CMX001 for the Treatment of Serious or Life-threatening Diseases Caused by Double-stranded DNA Viruses.

Mommeja-Marin H, Brundage T, Chittick G. Poster Baseline Characteristics of Patients Treated w/ CMX001 for Serious or Life-Threatening dsDNA Viruses. 2013 April. EBMT.

Mommeja-Marin H, Brundage T, Margolskee D. Poster Renal Safety of CMX001, in the Prevention of CMV Infection Post-Allogeneic HSCT. 2013 February. BMT.

Mommeja-Marin H, Brundage T, Margolskee D. Poster Changes in Serum Albumin Concentrations as an Indicator of Potential CMX001-associated GI Events 2013. February. BMT.

Papanicolaou G, Kolitsopoulos Y, Young J, et al. Poster Report of 5 Cases of BK Virus-Associated Nephropathy and the Potential Role of CMX001 for Treatment. 2013 February. BMT.